Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV Artesunate vs IV Artesunate plus IV Quinine in severe malaria
NCT06472258Completed
- Sponsor
- RESnTEC (Research and Technology) Ltd
- Start
- Mar 2023
- Primary completion
- Jun 2023
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Randomised, open-label trial of quinine in malaria, sponsored by RESnTEC (Research and Technology) Ltd. Primary endpoint: Efficacy measurement at 7 days. Started Mar 2023; status: completed.
02
Drugs
quinine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT06472258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06472258.